Belanatamab withdrawn: @oncology RT @CancerDoc: The #BCMA #ADC belanatamab mafodin-blmf was withdrawn from the US (#AcceleratedApproval in August 2008) after DREAMM-3 P3 confirmatory trial (belantamab vs. PomDex) for patients with #RRMM showed that PFS did not reach statistical significance (11.2 vs 7 months; HR, 1.03; 95% CI, 0.72 – 1.47). Another example that #FDA #AcceleratedApproval mechanism works as it should!!!
#fda #rrmm #acceleratedapproval #adc #BCMA
The #BCMA #ADC belanatamab mafodin-blmf was withdrawn from the US (#AcceleratedApproval in August 2008) after DREAMM-3 P3 confirmatory trial (belantamab vs. PomDex) for patients with #RRMM showed that PFS did not reach statistical significance (11.2 vs 7 months; HR, 1.03; 95% CI, 0.72 – 1.47). Another example that #FDA #AcceleratedApproval mechanism works as it should!!!
#bcma #adc #acceleratedapproval #rrmm #FDA